3-Adamantan-1-yl-2-hydroxy-N-[3-(3-morpholin-4-yl-propoxy)-phenyl]-propionamide | 1143465-90-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Adamantan-1-yl-2-hydroxy-N-[3-(3-morpholin-4-yl-propoxy)-phenyl]-propionamide
• 英文别名: 3-(1-adamantyl)-2-hydroxy-N-[3-(3-morpholin-4-ylpropoxy)phenyl]propanamide
• CAS: 1143465-90-0
• 化学式: C₂₆H₃₈N₂O₄
• 分子量: 442.599
• InChiKey: KOLANRYOTHLHJT-UHFFFAOYSA-N

物化性质

• 沸点：
  647.0±55.0 °C(predicted)
• 密度：
  1.200±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  71
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Adamantan-1-yl-2-hydroxy-N-[3-(3-morpholin-4-yl-propoxy)-phenyl]-propionamide 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-Adamantan-1-yl-N-[3-(3-morpholin-4-yl-propoxy)-phenyl]-2-oxo-propionamide
  参考文献：
  名称：

  Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors

  摘要：

  Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.013
• 作为产物：
  描述：

  3-[3-(morpholino)propoxy]benzenamine 、 rac-3-(1-adamantyl)-lactic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 3-Adamantan-1-yl-2-hydroxy-N-[3-(3-morpholin-4-yl-propoxy)-phenyl]-propionamide
  参考文献：
  名称：

  Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors

  摘要：

  Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.013

文献信息

• Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors
  作者：Sampath-Kumar Anandan、Zung N. Do、Heather K. Webb、Dinesh V. Patel、Richard D. Gless

  DOI：10.1016/j.bmcl.2009.01.013

  日期：2009.2

  Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea. (C) 2009 Elsevier Ltd. All rights reserved.